ZURICH, Dec 16 (Reuters) - Swiss drugmaker Roche Holding AG said it has filed for European approval of Avastin (bevacizumab) for the treatment of patients with previously treated glioblastoma, the most aggressive type of brain cancer.
ZURICH, Dec 16 (Reuters) - Swiss drugmaker Roche Holding AG said it has filed for European approval of Avastin (bevacizumab) for the treatment of patients with previously treated glioblastoma, the most aggressive type of brain cancer.